| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|
Growth matrix (%) | |||
Revenue growth | 27.08 | 31.5 | |
Op profit growth | 15.96 | 36.29 | |
EBIT growth | 21.33 | 33.81 | |
Net profit growth | 21.53 | 28.99 | |
Profitability ratios (%) | |||
OPM | 34.31 | 37.6 | 36.28 |
EBIT margin | 36.89 | 38.64 | 37.97 |
Net profit margin | 27.53 | 28.79 | 29.35 |
RoCE | 24.51 | 27.53 | |
RoNW | 4.63 | 5.21 | |
RoA | 4.57 | 5.12 | |
Per share ratios (₹) | |||
EPS | 73.75 | 60.94 | 49.88 |
Dividend per share | 0 | 0 | 0 |
Cash EPS | 67.03 | 54.9 | 43.77 |
Book value per share | 435.63 | 360.84 | 235.31 |
Valuation ratios | |||
P/E | 44.32 | 40.65 | |
P/CEPS | 48.76 | 45.13 | |
P/B | 7.5 | 6.86 | |
EV/EBIDTA | 29.19 | 26.11 | |
Payout (%) | |||
Dividend payout | 0 | 0 | 0 |
Tax payout | -25.13 | -25.31 | -22.15 |
Liquidity ratios | |||
Debtor days | 72.39 | 67.07 | |
Inventory days | 102.05 | 107.06 | |
Creditor days | -56.82 | -57.84 | |
Leverage ratios | |||
Interest coverage | -309.76 | -392.32 | -139.24 |
Net debt / equity | -0.43 | -0.5 | -0.36 |
Net debt / op. profit | -2.04 | -2.3 | -1.38 |
Cost breakup (₹) | |||
Material costs | -47.92 | -43.08 | -41.85 |
Employee costs | -7.69 | -8.99 | -10.54 |
Other costs | -10.06 | -10.32 | -11.32 |
The European business reported a 54 percent year on year surge in topline during the quarter.
Here are some of the stocks that may see significant price movement today: Infosys, Tata Steel, Cipla Limited, etc.
Here are some of the stocks that may see significant price movement: Bharti Airtel, Cipla, Gland Pharma, etc.
Here are some of the stocks that may see significant price movement today: Avenue Supermarts, BEML, Gland Pharma, etc.
The receipt of the EIR marks the formal closure of the US health regulator’s pre-approval inspection, which was conducted between February 19 and February 25, 2025.
Here are some of the stocks that may see significant price movement today: Hindustan Aeronautics, Gland Pharma, REC, etc.
Gland Pharma also established that its version is bioequivalent and therapeutically equivalent to the reference listed drug.
Gland Pharma net profit was at ₹186.5 crore as against ₹192.4 crore in the year-ago quarter of FY24.
Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US
The FDA conducted the pre-approval inspection (PAI) from Feb. 19, 2025, to Feb. 25, 2025, as part of the regulatory process for sterile APIs.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
